Blog

President of the EORTC on the necessity of having a better balance between industry and academia in clinical trials – European Cancer Organisation

oncologie.nu

Nov 22, 2024, 16:13

President of the EORTC on the necessity of having a better balance between industry and academia in clinical trials – European Cancer Organisation

European Cancer Organisation shared on LinkedIn:

“Research in cancer care is in the spotlight at this year’s European Cancer Summit .

Winette van der Graaf, president of the European Organisation for Research and Treatment of Cancer (EORTC) and ECO Board Member, highlighted during the Research Policy session the necessity of having a better balance between industry and academia in clinical trials: ‘About 85% of clinical trials are pharma-company led. Academics are under pressure. Being awarded some publicly funded grants helps us continue our research, but we want to do more.'”

European Cancer Organisation

EORTC shared this post on LinkedIn, adding:

“EORTC President Winette van der Graaf spoke today at the European Cancer Summit.

She presented the vital role that EORTC plays in clinical Cancer Research, while emphasising the need for greater patient involvement to drive meaningful change and improve practices in cancer care.”

More posts featuring ECO and EORTC.

Dr. Winette van der Graaf is the President of the European Organization for Research and Treatment of Cancer (EORTC). She is a professor and the head of medical oncology Department at the Netherlands Cancer Institute (Amsterdam), Professor of Oncology at Erasmus MC (Rotterdam). Dr. van der Graaf is a Board member of the European Cancer Organisation (ECO), Board member of the Connective Tissue Oncology (CTOS). Her research is focused on adolescent and young adult (AYA) cancer and sarcomas.